Author | Publication time | Design | Groups | Intervention | Outcomes | Jadad/ NOS score |
---|---|---|---|---|---|---|
Tien et al. (Tien et al. 2016) | 2016 | RCT | Dex (n = 20) | Dex 8 mg at induction | Maximal glucose change, glucose levels, insulin required | 7 |
C (n = 24) | Ondansetron 4 mg at induction | |||||
Nazar et al. (Nazar et al. 2009) | 2009 | RCT | Dex (n = 15) | Dex 8 mg at induction | Maximal glucose change, glucose levels | 4 |
C (n = 15) | Saline at induction | |||||
Corcoran et al. (Corcoran et al. 2021a) | 2020 | RCT | Dex (4) (n = 22) | Dex 4 mg at induction | Maximal glucose change, glucose levels, wound infection and dehiscence | 5 |
Dex (8) (n = 19) | Dex 8 mg at induction | |||||
C (n = 22) | Saline at induction | |||||
Backes et al. (Backes et al. 2013) | 2013 | RCT | Dex (n = 41) | Dex 10 mg at induction | Maximal glucose change, maximal glucose level | 6 |
C (n = 37) | No treatment | |||||
Nazar et al. (Nazar et al. 2011) | 2011 | RCT | Dex (n = 15) | Dex 8 mg at induction | Maximal glucose, glucose levels | 4 |
C (n = 15) | Saline at induction | |||||
Purushothaman et al. (Purushothaman et al. 2018) | 2018 | RCT | Dex (4) (n = 45) | Dex 4 mg pre-anesthesia | Maximal glucose, glucose levels | 4 |
Dex (8) (n = 45) | Dex 8 mg pre-anesthesia | |||||
C (n = 45) | Saline pre-anesthesia | |||||
Zhang et al. (Zhang et al. 2014) | 2014 | RCT | Dex (n = 10) | Dex 10 mg pre-anesthesia | Maximal glucose change, glucose levels | 3 |
C (n = 10) | Saline pre-anesthesia | |||||
Shang et al. (Shang et al. 2022) | 2022 | RCT | Dex (n = 45) | Dex 0.11 mg/kg post-induction | Glucose levels, insulin required, wound infection and dehiscence | 4 |
C (n = 45) | Saline post-induction | |||||
Corcoran et al. (Corcoran et al. 2021b) | 2021 | RCT | Dex (n = 583) | Dex 8 mg at induction | Wound infection | 7 |
C (n = 571) | Saline at induction | |||||
Wasfie et al. (Wasfie et al. 2018) | 2018 | Cohort study | Dex (n = 119) | Dex intraoperative | Glucose levels | 7 |
C (n = 235) | No treatment | |||||
Herbst et al. (Herbst et al. 2020) | 2020 | Cohort study | Dex (n = 626) | Dex perioperative | Maximal glucose, glucose levels | 7 |
C (n = 520) | No treatment | |||||
Godshaw et al. (Godshaw et al. 2019) | 2019 | Cohort study | Dex (n = 428) | Dex 6 or 12 mg pre-incision | Glucose levels, infection | 6 |
C (n = 229) | No treatment | |||||
Allen et al. (Allen et al. 2020) | 2020 | Cohort study | Dex (n = 92) | Dex 8 mg pre-incision | Maximal glucose,glucose levels, insulin required | 7 |
C (n = 193) | No treatment | |||||
Egan et al. (Egan et al. 2019) | 2019 | Cohort study | Dex (n = 17) | Dex 4 or 10 mg intraoperative | Glucose levels, Insulin requirement, wound infection and dehiscence | 6 |
C (n = 104) | No treatment | |||||
Harding et al. (Harding et al. 2021) | 2021 | Cohort study | Dex (n = 173) | Dex 4–10 mg intraoperative | Hyperglycemia, glucose levels, wound infection | 7 |
C (n = 55) | No treatment | |||||
O’Connell et al. (O'Connell et al. 2018) | 2018 | Cohort study | Dex (n = 77) | Dex intraoperative | Glucose levels | 7 |
C (n = 161) | No treatment |